Lv11
100 积分 2023-06-05 加入
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2天前
已完结
Rational combinations of targeted cancer therapies: background, advances and challenges
2天前
已完结
Tumour heterogeneity and resistance to cancer therapies
2天前
已完结
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
2天前
已完结
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2天前
已完结
Inflammation and immune biomarkers: new frontiers in understanding and managing diabetes complications
3天前
已完结
Epidemiology of Spondyloarthritis in the People’s Republic of China: Review of the Literature and Commentary
5天前
已完结
Remimazolam Dosing for Gastroscopy: A Randomized Noninferiority Trial
6天前
已完结
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)
11天前
已完结
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
11天前
已完结
皖公网安备34019202002308
